Pidnarulex
Phase 1Small molecule
Pidnarulex is one of 129 small molecule programs targeting Lymphoma. It is currently in Phase 1.
6
Indications
5
Total Trials
4
Active Trials
128
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
2828 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Tecentriq
RochePreclinical
Adriamycin
GGynecologic Oncology Group
Preclinical
Prolia
AmgenPreclinical
Gemzar
GGynecologic Oncology Group
Preclinical
Pidnarulex
NNational Cancer Institute (NCI)
Phase 1
Lupron
EEastern Cooperative Oncology Group
Preclinical
Methylthioninium Chloride
PProvepharm SAS
Preclinical
Fentanyl Citrate
IINSYS Therapeutics Inc
Preclinical
Vit D
PPost Graduate Institute of Medical Education and Research, Chandigarh
Preclinical
Dextromethorphan Hydrobromide
Boehringer IngelheimPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Lymphoma1 trial
Prostate Cancer1 trial
Metastatic Solid Cancers1 trial
Anatomic Stage III Breast Cancer AJCC v81 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Pidnarulex. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- NNational Cancer Institute (NCI)